Primary Record
Imatinib mesylate
- In stock
- 8,986 g
- Purity
- 98.4 %
- CAS
- 220127-57-1
Compound Identifiers & Properties
- CAS
- 220127-57-1
- PubChem CID
- 123596
- SMILES
- CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5.CS(=O)(=O)O
- Canonical SMILES
- CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Names & Synonyms
- Imatinib mesylate
- Gleevec
- Glivec
- 220127-57-1
- Imatinib mesilate
- imatinib methanesulfonate
- Imatinib
- Imatinib accord
- Imatinib medac
- sti-571
- Genfatinib
- Shantinib
- Gleevac
- imatinib oral
- ImatinibMesylate
- Imatinib Mesylate (STI571)
- Imatinb Mesylate
- Gleevec;
- imatinib monomesylate
- Imatinib (mesylate)
- IMKELDI
- Imatinib mesylate;
- Imatinib mesylate?
- Imatinib (as mesilate)
- Mesylate, Imatinib
- Gleevec (TN)
- Glivec (TN)
- Imatinib methane sulfonate
- RefChem:77
- STI571
- Imatinib mesilate CRS
- Imatinib(free base)?
- Gleevec (Imatinib mesylate)
- ST-1571 Mesylate
- Imatinib Methansulfonate
- Imatinib mesylate [USAN]
- STI 571
- Imatinib Mesylate/Glivec
- Imatinib mesilate (JAN)
- imatinib mesylate mesylate
- Imatinib Mesylate Tablets
- QTI-571
- QTI571
- Methanesulfonate, Imatinib
- CGP-57148B
- DTXSID9040502
- Imatinib mesylate (USAN)
- MFCD04307699
- D0Z6KI
- Imatinib mesylate 400 mg
- AC1L3WY1
- Imatinib, methanesulfonate salt
- SCHEMBL8217
- Imatinib Mesylate(|A form)
- Imatinib monomethanesulfonate
- NSC-716051
- 8A1O1M485B
- CGP 57148B
- CHEMBL1642
- IMATINIB MESYLATE 1G
- Benzamide,monomethanesulfonate
- 220127-57-1 (mesylate)
- DTXCID7020502
- Imatinib methanesulfonate salt
- C30H35N7O4S
- cc-159
- CHEBI:31690
- HSDB 7142
- MLS001401456
- UNII-8A1O1M485B
- orb1307991
- Cgp 57148
- IMATINIB MESILATE [JAN]
- C29H31N7O.CH4SO3
- Imatinib (Mesylate) (Standard)
- IMATINIB MESYLATE [HSDB]
- IMATINIB MESYLATE 100MG
- SCHEMBL15632914
- SCHEMBL29370699
- SCHEMBL29377238
- CGP57148B
- AOB6752
- CGP-571
- EX-A954
- IMATINIB MESYLATE [VANDF]
- SYN1046
- CGP-57148
- IMATINIB MESILATE [MART.]
- NSC716051
- YLMAHDNUQAMNNX-UHFFFAOYSA-N
- 4-Fluoro-3-nitrophenyl isocyanate
- BCPP000204
- GGP-57148B
- GLXC-05064
- HMS2052B09
- HMS2233D16
- HMS3265E01
- HMS3265E02
- HMS3265F01
- HMS3265F02
- HMS3372O12
- HMS3394B09
- HMS3654C07
- HMS5079E05
- IMATINIB MESILATE [WHO-DD]
- ACT05102
- BCP01255
- CGP57148
- EBD22648
- Imatinib for system suitability CRS
- KS-000002AE
- Tox21_111684
- ABP000865
- AC-525
- CGP 53715
- CI0026
- CID123596
- FC0015
- HB1943
- HY-50946R
- NP3279
- RS0020
- s1026
- Imatinib mesylate - Bio-X trade mark
- IMATINIB METHANESULFONATE [MI]
- AKOS015852497
- Tox21_111684_1
- ACN-034468
- AN-5298
- BCP9000776
- CCG-101175
- CS-0027
- FI10812
- IMATINIB MESYLATE [ORANGE BOOK]
- KS-1236
- NC00425
- NSC 716051
- TRA0018756
- IMATINIB MESILATE [EP MONOGRAPH]
- Imatinib mesylate =98.0% (by HPLC)
- NCGC00159456-02
- NCGC00159456-11
- 111GE005
- AK-44930
- BC215795
- BI164678
- CPD000469175
- HY-50946
- LS-27113
- SAM001246622
- SMR000469175
- SY013513
- M06311
- AB0005762
- AB1008575
- Imatinib mesylate, 98% - 250MG 250mg
- ST2413118
- TL8001825
- TL8006192
- AM20080900
- CAS-220127-57-1
- FT-0601612
- I0936
- NS00076459
- SW197805-4
- EC-000.2338
- A-2359
- A10468
- D01441
- Imatinib Mesylate (CGP-57148B, STI-571)
- J10205
- 152459-95-5
- 45150-EP2270008A1
- 45150-EP2277867A2
- 45150-EP2280003A2
- 45150-EP2289893A1
- 45150-EP2292617A1
- 45150-EP2298768A1
- 45150-EP2305682A1
- 45150-EP2308861A1
- 45150-EP2308879A1
- 45150-EP2311821A1
- N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide methanesulfonate
- 127I571
- A815828
- A846640
- 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide monomethanesulfonate
- I06-0363
- Q27114666
- Imatinib Mesylate,Gleevec,Glivec,CGP-57148B,STI-571
- Imatinib Mesylate/Gleevec, Glivec, CGP-57148B, STI-571
- 4-[(4-methyl-1-piperazinyl)methyl]-n-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide methanesulfonate
- Benzamide, 4-((4-methyl-1-piperazinyl)methyl)-N-(4-methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)phenyl)-, monomethanesulfonate
- Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (1:1)
- Imatinib Mesylate Multi-target kinase inhibitor of abl, c-kit, and PDGFR
- methanesulfonic acid; 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
- methanesulfonic acid;4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
- N-(4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide methanesulfonate
- alpha-(4-Methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-tolu-p-toluidide
- ;4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide methanesulfonate
- 4-((4-Methyl-1-piperazinyl)methyl)-N-(4-methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)phenyl)benzamide Monomethanesulfonate
- 4-(4-Methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin- 3-yl)-pyrimidin-2-ylamino)-phenyl]-benzamidemethanesulfonic acid salt
- 4-(4-Methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide methanesulfonic acid salt
- 4-(4-Methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)phenyl]benzamide methanesulfonic acid salt
- 4-[(4-Methyl-1-piperazinyl)-methyl]-N-{4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]-amino]-phenyl}-benzamide monomethanesulphonate
- 4-[(4-methyl-1-piperazinyl)methyl]-n-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl]benzamide methanesulfonate
- 4-[(4-Methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide mesylate
- 4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl) amino]phenyl]benzamide methanesulfonate
- 4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide methanesulfonate
- 4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
- 4-[(4-methylpiperazin-1-yl)methyl]-N-{4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl}benzamide methanesulfonate
- Benzamide, 4-((4-methyl-1-piperazinyl)methyl)-N-(4-methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)phenyl)-monomethanesulfonate
- Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (1:1); Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI); 1-Methyl-4-(4-((4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)carbamoyl)benzyl)piperazine methanesulfonate; CGP 57148B; Gleevac; Gleevec; Glivec; Imatinib mesilate; Imatinib mesylate; Mitinab; STI 571
- Benzamide,4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-,methanesulfonate (1:1)
- hydron;methanesulfonate;4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
- Methanesulfonic acid--4-[(4-methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide (1/1)
- methanesulfonic acid; 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide
- methanesulfonic acid; 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[[4-(3-pyridyl)pyrimidin-2-yl]amino]phenyl]benzamide
- methanesulfonic acid;4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[[4-(3-pyridyl)pyrimidin-2-yl]amino]phenyl]benzamide
- N-(4-methyl-3(4-(pyridin-3-yl)pyridin-2-ylamino)phenyl-4-((4-methylpiperazin-1-yl)methyl)benzamide
- N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamidemethanesulfonate